Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Pioglitazone, Bladder Cancer, and the Presumption of Innocence

Author(s): Georgios S. Papaetis

Volume 17, Issue 4, 2022

Published on: 14 April, 2022

Page: [294 - 318] Pages: 25

DOI: 10.2174/1574886317666220304124756

Price: $65

Abstract

Background: Thiazolidinediones are potent exogenous agonists of PPAR-γ that augment the effects of insulin to its cellular targets, mainly at the level of adipose tissue. Pioglitazone, the main thiazolidinedione in clinical practice, has shown cardiovascular and renal benefits in patients with type 2 diabetes, durable reduction of glycated hemoglobulin levels, important improvements of several components of the metabolic syndrome, and beneficial effects of non-alcoholic fatty liver disease.

Objective: Despite all of its established advantages, the controversy for an increased risk of developing bladder cancer, combined with the advent of newer drug classes that achieved major cardiorenal effects, have significantly limited its use spreading a persistent shadow of doubt for its future role.

Methods: Pubmed, Google, and Scope databases have been thoroughly searched, and relevant studies were selected.

Results: This paper thoroughly explores both in vitro and in vivo (animal models and humans) studies that investigated the possible association of pioglitazone with bladder cancer.

Conclusion: Currently, the association of pioglitazone with bladder cancer cannot be based on solid evidence. This evidence cannot justify its low clinical administration, especially in the present era of individualised treatment strategies. Definite clarification of this issue is imperative and urgently anticipated from future high quality and rigorous pharmacoepidemiologic research, keeping in mind its unique mechanism of action and its significant pleiotropic effects.

Keywords: Pioglitazone, thiazolidinediones, bladder cancer, diabetes mellitus, insulin resistance, pharmacoepi demiology.

« Previous Next »
Graphical Abstract

[1]
Papaetis GS, Orphanidou D, Panagiotou TN. Thiazolidinediones and type 2 diabetes: From cellular targets to cardiovascular benefit. Curr Drug Targets 2011; 12(10): 1498-512.
[http://dx.doi.org/10.2174/138945011796818243] [PMID: 21675944]
[2]
Bays H, Mandarino L, DeFronzo RA. Role of the adipocytes, FFA, and ectopic fat in the pathogenesis of type 2 diabetes mellitus: PPAR agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004; 89(2): 463-78.
[http://dx.doi.org/10.1210/jc.2003-030723] [PMID: 14764748]
[3]
Wang S, Dougherty EJ, Danner RL. PPARγ signaling and emerging opportunities for improved therapeutics. Pharmacol Res 2016; 111: 76-85.
[http://dx.doi.org/10.1016/j.phrs.2016.02.028] [PMID: 27268145]
[4]
Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev 2002; 18(Suppl. 2): S10-5.
[http://dx.doi.org/10.1002/dmrr.249] [PMID: 11921433]
[5]
Papaetis GS, Papakyriakou P, Panagiotou TN. Central obesity, type 2 diabetes and insulin: exploring a pathway full of thorns. Arch Med Sci 2015; 11(3): 463-82.
[http://dx.doi.org/10.5114/aoms.2015.52350] [PMID: 26170839]
[6]
Pfützner A, Marx N, Lübben G, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: Results from the pioneer study. J Am Coll Cardiol 2005; 45(12): 1925-31.
[http://dx.doi.org/10.1016/j.jacc.2005.03.041] [PMID: 15963388]
[7]
DeFronzo RA, Inzucchi S, Abdul-Ghani M, Nissen SE. Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. Diab Vasc Dis Res 2019; 16(2): 133-43.
[http://dx.doi.org/10.1177/1479164118825376] [PMID: 30706731]
[8]
Armato J, DeFronzo RA, Abdul-Ghani M, Ruby R. Successful treatment of prediabetes in clinical practice: Targeting insulin resistance and β-cell dysfunction. Endocr Pract 2012; 18(3): 342-50.
[http://dx.doi.org/10.4158/EP11194.OR] [PMID: 22068250]
[9]
Tripathy D, Schwenke DC, Banerji M, et al. Diabetes incidence and glucose tolerance after termination of pioglitazone therapy: Results from act now. J Clin Endocrinol Metab 2016; 101(5): 2056-62.
[http://dx.doi.org/10.1210/jc.2015-4202] [PMID: 26982008]
[10]
Stringer F, DeJongh J, Enya K, Koumura E, Danhof M, Kaku K. Evaluation of the long-term durability and glycemic control of fasting plasma glucose and glycosylated hemoglobin for pioglitazone in Japanese patients with type 2 diabetes. Diabetes Technol Ther 2015; 17(3): 215-23.
[http://dx.doi.org/10.1089/dia.2014.0222] [PMID: 25531677]
[11]
Vu A, Kosmiski LA, Beitelshees AL, et al. Pharmacodynamic effects of low-dose pioglitazone in patients with the metabolic syndrome without diabetes mellitus. Pharmacotherapy 2016; 36(3): 252-62.
[http://dx.doi.org/10.1002/phar.1713] [PMID: 26822630]
[12]
Sarafidis PA, Stafylas PC, Georgianos PI, Saratzis AN, Lasaridis AN. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: A meta-analysis. Am J Kidney Dis 2010; 55(5): 835-47.
[http://dx.doi.org/10.1053/j.ajkd.2009.11.013] [PMID: 20110146]
[13]
Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: A randomized trial. Ann Intern Med 2016; 165(5): 305-15.
[http://dx.doi.org/10.7326/M15-1774] [PMID: 27322798]
[14]
Panunzi S, Maltese S, Verrastro O, et al. Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: A hierarchical network meta-analysis. Diabetes Obes Metab 2021; 23(4): 980-90.
[http://dx.doi.org/10.1111/dom.14304] [PMID: 33368954]
[15]
Yen CL, Wu CY, See LC, et al. Pioglitazone reduces mortality and adverse events in patients with type 2 diabetes and with advanced chronic kidney disease: National cohort study. Diabetes Care 2020; 43(10): e152-3.
[http://dx.doi.org/10.2337/dc20-1584] [PMID: 32801131]
[16]
Fiorentino TV, Monroy A, Kamath S, et al. Pioglitazone corrects dysregulation of skeletal muscle mitochondrial proteins involved in ATP synthesis in type 2 diabetes. Metabolism 2021; 114: 154416.
[http://dx.doi.org/10.1016/j.metabol.2020.154416] [PMID: 33137378]
[17]
Kermode-Scott B. Meta-analysis confirms raised risk of bladder cancer from pioglitazone. BMJ 2012; 345: e4541.
[http://dx.doi.org/10.1136/bmj.e4541] [PMID: 22763399]
[18]
Kostapanos MS, Elisaf MS, Mikhailidis DP. Pioglitazone and cancer: Angel or demon? Curr Pharm Des 2013; 19(27): 4913-29.
[http://dx.doi.org/10.2174/13816128113199990294] [PMID: 23278487]
[19]
Bazelier MT, de Vries F, Vestergaard P, Leufkens HG, De Bruin ML. Use of thiazolidinediones and risk of bladder cancer: Disease or drugs? Curr Drug Saf 2013; 8(5): 364-70.
[http://dx.doi.org/10.2174/15748863113086660069] [PMID: 24215315]
[20]
Fernandez-Fernandez B, Sarafidis P, Kanbay M, et al. SGLT2 inhibitors for non-diabetic kidney disease: Drugs to treat CKD that also improve glycaemia. Clin Kidney J 2020; 13(5): 728-33.
[http://dx.doi.org/10.1093/ckj/sfaa198] [PMID: 33123352]
[21]
Papaetis GS. Empagliflozin and the diabetic kidney: Pathophysiological concepts and future challenges. Endocr Metab Immune Disord Drug Targets 2021; 21(9): 1555-89.
[http://dx.doi.org/10.2174/1871530321999201214233421] [PMID: 33319678]
[22]
Papaetis GS. Incretin-based therapies in prediabetes: Current evidence and future perspectives. World J Diabetes 2014; 5(6): 817-34.
[http://dx.doi.org/10.4239/wjd.v5.i6.817] [PMID: 25512784]
[23]
Papaetis GS. Liraglutide therapy in a prediabetic state: Rethinking the evidence. Curr Diabetes Rev 2020; 16(7): 699-715.
[http://dx.doi.org/10.2174/1573399816666191230113446] [PMID: 31886752]
[24]
Papaetis GS, Filippou PK, Constantinidou KG, Stylianou CS. Liraglutide: New perspectives for the treatment of polycystic ovary syndrome. Clin Drug Investig 2020; 40(8): 695-713.
[http://dx.doi.org/10.1007/s40261-020-00942-2] [PMID: 32583294]
[25]
Davidson MB. Pioglitazone (Actos) and bladder cancer: Legal system triumphs over the evidence. J Diabetes Complications 2016; 30(6): 981-5.
[http://dx.doi.org/10.1016/j.jdiacomp.2016.04.004] [PMID: 27133452]
[26]
Sinha B, Ghosal S. Pioglitazone--do we really need it to manage type 2 diabetes? Diabetes Metab Syndr 2013; 7(4): 243-6.
[http://dx.doi.org/10.1016/j.dsx.2013.06.005] [PMID: 24290093]
[27]
Grosse Y, Loomis D, Lauby-Secretan B, et al. International agency for research on cancer monograph working group. Carcinogenicity of some drugs and herbal products. Lancet Oncol 2013; 14(9): 807-8.
[http://dx.doi.org/10.1016/S1470-2045(13)70329-2] [PMID: 24058961]
[28]
Engler C, Leo M, Pfeifer B, et al. Long-term trends in the prescription of antidiabetic drugs: Real-world evidence from the Diabetes Registry Tyrol 2012-2018. BMJ Open Diabetes Res Care 2020; 8(1): e001279.
[http://dx.doi.org/10.1136/bmjdrc-2020-001279] [PMID: 32873600]
[29]
Cid Ruzafa J, Ulrichsen SP, Bennett D, Ehrenstein V. Post-authorisation safety study of pioglitazone use and safety endpoints of interest in Denmark after direct healthcare professional communication. Drugs Real World Outcomes 2019; 6(3): 133-40.
[http://dx.doi.org/10.1007/s40801-019-0160-6] [PMID: 31376066]
[30]
Spiegelman BM. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47(4): 507-14.
[http://dx.doi.org/10.2337/diabetes.47.4.507] [PMID: 9568680]
[31]
Christodoulides C, Vidal-Puig A. PPARs and adipocyte function. Mol Cell Endocrinol 2010; 318(1-2): 61-8.
[http://dx.doi.org/10.1016/j.mce.2009.09.014] [PMID: 19772894]
[32]
Guan Y, Zhang Y, Davis L, Breyer MD. Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans. Am J Physiol 1997; 273(6): F1013-22.
[PMID: 9435691]
[33]
Jain S, Pulikuri S, Zhu Y, et al. Differential expression of the peroxisome proliferator-activated receptor γ (PPARgamma) and its coactivators steroid receptor coactivator-1 and PPAR-binding protein PBP in the brown fat, urinary bladder, colon, and breast of the mouse. Am J Pathol 1998; 153(2): 349-54.
[http://dx.doi.org/10.1016/S0002-9440(10)65577-0] [PMID: 9708794]
[34]
Liu C, Tate T, Batourina E, et al. Pparg promotes differentiation and regulates mitochondrial gene expression in bladder epithelial cells. Nat Commun 2019; 10(1): 4589.
[http://dx.doi.org/10.1038/s41467-019-12332-0] [PMID: 31597917]
[35]
Shu L, Huang R, Wu S, et al. PPARgamma and its ligands: Potential antitumor agents in the digestive system. Curr Stem Cell Res Ther 2016; 11: 274-81.
[http://dx.doi.org/10.2174/1574888X10666150630111618] [PMID: 26122910]
[36]
Yousefnia S, Momenzadeh S, Seyed Forootan F, Ghaedi K, Nasr Esfahani MH. The influence of Peroxisome Proliferator-Activated Receptor γ (PPARγ) ligands on cancer cell tumorigenicity. Gene 2018; 649: 14-22.
[http://dx.doi.org/10.1016/j.gene.2018.01.018] [PMID: 29369787]
[37]
Mushtaq J, Thurairaja R, Nair R. Bladder cancer. Surgery 2019; 37(9): 529-37.
[http://dx.doi.org/10.1016/j.mpsur.2019.07.003]
[38]
Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of bladder cancer. Med Sci (Basel) 2020; 8(1): 15.
[http://dx.doi.org/10.3390/medsci8010015] [PMID: 32183076]
[39]
Choi W, Porten S, Kim S, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 2014; 25(2): 152-65.
[http://dx.doi.org/10.1016/j.ccr.2014.01.009] [PMID: 24525232]
[40]
Fong MHY, Feng M, McConkey DJ, Choi W. Update on bladder cancer molecular subtypes. Transl Androl Urol 2020; 9(6): 2881-9.
[http://dx.doi.org/10.21037/tau-2019-mibc-12] [PMID: 33457262]
[41]
Blaveri E, Simko JP, Korkola JE, et al. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res 2005; 11(11): 4044-55.
[http://dx.doi.org/10.1158/1078-0432.CCR-04-2409] [PMID: 15930339]
[42]
Dadhania V, Zhang M, Zhang L, et al. Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use. EBioMedicine 2016; 12: 105-17.
[http://dx.doi.org/10.1016/j.ebiom.2016.08.036] [PMID: 27612592]
[43]
Biton A, Bernard-Pierrot I, Lou Y, et al. Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypes. Cell Rep 2014; 9(4): 1235-45.
[http://dx.doi.org/10.1016/j.celrep.2014.10.035] [PMID: 25456126]
[44]
Goldstein JT, Berger AC, Shih J, et al. Genomic activation of PPARG reveals a candidate therapeutic axis in bladder cancer. Cancer Res 2017; 77(24): 6987-98.
[http://dx.doi.org/10.1158/0008-5472.CAN-17-1701] [PMID: 28923856]
[45]
Cheng S, Qian K, Wang Y, et al. PPARγ inhibition regulates the cell cycle, proliferation and motility of bladder cancer cells. J Cell Mol Med 2019; 23(5): 3724-36.
[http://dx.doi.org/10.1111/jcmm.14280] [PMID: 30912275]
[46]
Peng T, Wang G, Cheng S, et al. The role and function of PPARγ in bladder cancer. J Cancer 2020; 11(13): 3965-75.
[http://dx.doi.org/10.7150/jca.42663] [PMID: 32328200]
[47]
Fauconnet S, Lascombe I, Chabannes E, et al. Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells. J Biol Chem 2002; 277(26): 23534-43.
[http://dx.doi.org/10.1074/jbc.M200172200] [PMID: 11980898]
[48]
Egerod FL, Nielsen HS, Iversen L, Thorup I, Storgaard T, Oleksiewicz MB. Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo. Biomarkers 2005; 10(4): 295-309.
[http://dx.doi.org/10.1080/13547500500218682] [PMID: 16240504]
[49]
Zhang Z, Xu H, Ji J, et al. Heterogeneity of PTEN and PPAR-γ in cancer and their prognostic application to bladder cancer. Exp Ther Med 2019; 18(4): 3177-83.
[http://dx.doi.org/10.3892/etm.2019.7879] [PMID: 31555390]
[50]
Yoshimura R, Matsuyama M, Segawa Y, et al. Expression of Peroxisome Proliferator-Activated Receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer 2003; 104(5): 597-602.
[http://dx.doi.org/10.1002/ijc.10980] [PMID: 12594814]
[51]
Nakashiro KI, Hayashi Y, Kita A, et al. Role of peroxisome proliferator-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells. Am J Pathol 2001; 159(2): 591-7.
[http://dx.doi.org/10.1016/S0002-9440(10)61730-0] [PMID: 11485917]
[52]
Chaffer CL, Thomas DM, Thompson EW, Williams ED. PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer 2006; 6: 53.
[http://dx.doi.org/10.1186/1471-2407-6-53] [PMID: 16519808]
[53]
Lv S, Wang W, Wang H, Zhu Y, Lei C. PPARγ activation serves as therapeutic strategy against bladder cancer via inhibiting PI3K-Akt signaling pathway. BMC Cancer 2019; 19(1): 204.
[http://dx.doi.org/10.1186/s12885-019-5426-6] [PMID: 30845932]
[54]
Rochel N, Krucker C, Coutos-Thévenot L, et al. Recurrent activating mutations of PPARγ associated with luminal bladder tumors. Nat Commun 2019; 10(1): 253.
[http://dx.doi.org/10.1038/s41467-018-08157-y] [PMID: 30651555]
[55]
Korpal M, Puyang X, Jeremy Wu Z, et al. Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer. Nat Commun 2017; 8(1): 103.
[http://dx.doi.org/10.1038/s41467-017-00147-w] [PMID: 28740126]
[56]
Lodillinsky C, Umerez MS, Jasnis MA, Casabé A, Sandes E, Eiján AM. Bacillus Calmette-Guérin induces the expression of peroxisome proliferator-activated receptor gamma in bladder cancer cells. Int J Mol Med 2006; 17(2): 269-73.
[http://dx.doi.org/10.3892/ijmm.17.2.269] [PMID: 16391825]
[57]
Langle Y, Lodillinsky C, Belgorosky D, Sandes EO, Eiján AM. Role of peroxisome proliferator activated receptor-gamma in bacillus Calmette-Guérin bladder cancer therapy. J Urol 2012; 188(6): 2384-90.
[http://dx.doi.org/10.1016/j.juro.2012.07.109] [PMID: 23088980]
[58]
Rebouissou S, Bernard-Pierrot I, de Reyniès A, et al. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci Transl Med 2014; 6(244): 244ra91.
[http://dx.doi.org/10.1126/scitranslmed.3008970] [PMID: 25009231]
[59]
Mansure JJ, Nassim R, Chevalier S, et al. A novel mechanism of PPAR gamma induction via EGFR signalling constitutes rational for combination therapy in bladder cancer. PLoS One 2013; 8(2): e55997.
[http://dx.doi.org/10.1371/journal.pone.0055997] [PMID: 23409107]
[60]
Mehus AA, Bergum N, Knutson P, et al. Activation of PPARγ and inhibition of cell proliferation reduces key proteins associated with the basal subtype of bladder cancer in As3+-transformed UROtsa cells. PLoS One 2020; 15(8): e0237976.
[http://dx.doi.org/10.1371/journal.pone.0237976] [PMID: 32822399]
[61]
Wang G, Cao R, Wang Y, et al. Simvastatin induces cell cycle arrest and inhibits proliferation of bladder cancer cells via PPARγ signalling pathway. Sci Rep 2016; 6: 35783.
[http://dx.doi.org/10.1038/srep35783] [PMID: 27779188]
[62]
Cheng S, Wang G, Wang Y, et al. Fatty acid oxidation inhibitor etomoxir suppresses tumor progression and induces cell cycle arrest via PPARγ-mediated pathway in bladder cancer. Clin Sci (Lond) 2019; 133(15): 1745-58.
[http://dx.doi.org/10.1042/CS20190587] [PMID: 31358595]
[63]
Suzuki S, Arnold LL, Pennington KL, et al. Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. Toxicol Sci 2010; 113(2): 349-57.
[http://dx.doi.org/10.1093/toxsci/kfp256] [PMID: 19858066]
[64]
Yang SL, Wang JJ, Chen M, et al. Pioglitazone use and risk of bladder cancer: An in vitro study. Int J Med Sci 2018; 15(3): 228-37.
[http://dx.doi.org/10.7150/ijms.22408] [PMID: 29483814]
[65]
Fujimoto K, Yamada Y, Okajima E, et al. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 1992; 52(6): 1393-8.
[PMID: 1540947]
[66]
Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol 1994; 152(2 Pt 1): 388-92.
[http://dx.doi.org/10.1016/S0022-5347(17)32745-3] [PMID: 8015077]
[67]
Kopparapu PK, Boorjian SA, Robinson BD, et al. Expression of cyclin d1 and its association with disease characteristics in bladder cancer. Anticancer Res 2013; 33(12): 5235-42.
[PMID: 24324055]
[68]
Shahid M, Kim M, Yeon A, et al. Pioglitazone alters the proteomes of normal bladder epithelial cells but shows no tumorigenic effects. Int Neurourol J 2020; 24(1): 29-40.
[http://dx.doi.org/10.5213/inj.1938186.093] [PMID: 32252184]
[69]
Han Y, Jin X, Zhou H, Liu B. Identification of key genes associated with bladder cancer using gene expression profiles. Oncol Lett 2018; 15(1): 297-303.
[PMID: 29375713]
[70]
Kim D, Ahn BN, Kim Y, et al. High glucose with insulin induces cell cycle progression and activation of oncogenic signaling of bladder epithelial cells cotreated with metformin and pioglitazone. J Diabetes Res 2019; 2019: 2376512.
[http://dx.doi.org/10.1155/2019/2376512] [PMID: 30729133]
[71]
Atlı Şekeroğlu Z, Şekeroğlu V, Kontaş Yedier S, İlkun E, Liou LS. Increased DNA strand breaks and neoplastic transformation in human bladder cells treated with pioglitazone. Environ Mol Mutagen 2021; 62(2): 143-54.
[http://dx.doi.org/10.1002/em.22424] [PMID: 33496997]
[72]
Sakamoto J, Kimura H, Moriyama S, et al. Activation of human Peroxisome Proliferator-Activated Receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 2000; 278(3): 704-11.
[http://dx.doi.org/10.1006/bbrc.2000.3868] [PMID: 11095972]
[73]
Orasanu G, Ziouzenkova O, Devchand PR, et al. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice. J Am Coll Cardiol 2008; 52(10): 869-81.
[http://dx.doi.org/10.1016/j.jacc.2008.04.055] [PMID: 18755353]
[74]
Oleksiewicz MB, Southgate J, Iversen L, Egerod FL. Rat urinary bladder carcinogenesis by dual-acting PPARalpha + gamma agonists. PPAR Res 2008; 2008: 103167.
[http://dx.doi.org/10.1155/2008/103167] [PMID: 19197366]
[75]
Lubet RA, Fischer SM, Steele VE, Juliana MM, Desmond R, Grubbs CJ. Rosiglitazone, a PPAR gamma agonist: Potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers. Int J Cancer 2008; 123(10): 2254-9.
[http://dx.doi.org/10.1002/ijc.23765] [PMID: 18712722]
[76]
Tirmenstein M, Janovitz E, Dorr T, et al. Evaluation of uracil, sodium ascorbate, and rosiglitazone as promoters of urinary bladder transitional cell carcinomas in male Sprague-Dawley rats. Toxicol Pathol 2018; 46(2): 147-57.
[http://dx.doi.org/10.1177/0192623318756004] [PMID: 29471778]
[77]
Cohen SM. Effects of PPARgamma and combined agonists on the urinary tract of rats and other species. Toxicol Sci 2005; 87(2): 322-7.
[http://dx.doi.org/10.1093/toxsci/kfi266] [PMID: 16049269]
[78]
Hardisty JF, Anderson DC, Brodie S, et al. Histopathology of the urinary bladders of cynomolgus monkeys treated with PPAR agonists. Toxicol Pathol 2008; 36(6): 769-76.
[http://dx.doi.org/10.1177/0192623308323624] [PMID: 18776159]
[79]
Dominick MA, White MR, Sanderson TP, et al. Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: Evidence for urolithiasis as the inciting event in the mode of action. Toxicol Pathol 2006; 34(7): 903-20.
[http://dx.doi.org/10.1080/01926230601072327] [PMID: 17178691]
[80]
Van Vleet TR, White MR, Sanderson TP, et al. Subchronic urinary bladder effects of muraglitazar in male rats. Toxicol Sci 2007; 96(1): 58-71.
[http://dx.doi.org/10.1093/toxsci/kfl176] [PMID: 17132713]
[81]
Long GG, Reynolds VL, Lopez-Martinez A, Ryan TE, White SL, Eldridge SR. Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: Lack of evidence for urolithiasis as an inciting event. Toxicol Pathol 2008; 36(2): 218-31.
[http://dx.doi.org/10.1177/0192623307311757] [PMID: 18474944]
[82]
Lima BS, Dominick M, Iversen L, Oleksiewicz MB. Peroxisome proliferators activated receptors (PPARs) agonists and rodent tumorigenesis: updating the discussions Proceedings of the 42nd DIA Annual Meeting. Philadelphia, Pa, USA. BT Biotechnology/ NC Nonclinical Labaroratory Safety, 299D 2006.
[83]
Varley CL, Southgate J. Effects of PPAR agonists on proliferation and differentiation in human urothelium. Exp Toxicol Pathol 2008; 60(6): 435-41.
[http://dx.doi.org/10.1016/j.etp.2008.04.009] [PMID: 18571911]
[84]
Varley CL, Stahlschmidt J, Lee WC, et al. Role of PPARgamma and EGFR signalling in the urothelial terminal differentiation programme. J Cell Sci 2004; 117(Pt 10): 2029-36.
[http://dx.doi.org/10.1242/jcs.01042] [PMID: 15054105]
[85]
Tseng CH, Tseng FH. Peroxisome proliferator-activated receptor agonists and bladder cancer: Lessons from animal studies. J Environ Sci Health Part C Environ Carcinog Ecotoxicol Rev 2012; 30(4): 368-402.
[http://dx.doi.org/10.1080/10590501.2012.735519] [PMID: 23167631]
[86]
Mahal A, Young-Lin N, Dobberfuhl A, Estes J, Comiter CV. Peroxisome proliferator-activated receptor gamma agonist as a novel treatment for interstitial cystitis: A rat model. Investig Clin Urol 2018; 59(4): 257-62.
[http://dx.doi.org/10.4111/icu.2018.59.4.257] [PMID: 29984341]
[87]
Sato K, Awasaki Y, Kandori H, et al. Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats. Toxicol Appl Pharmacol 2011; 251(3): 234-44.
[http://dx.doi.org/10.1016/j.taap.2011.01.006] [PMID: 21255596]
[88]
Achanzar WE, Moyer CF, Marthaler LT, et al. Urine acidification has no effect on Peroxisome Proliferator-Activated Receptor (PPAR) signaling or Epidermal Growth Factor (EGF) expression in rat urinary bladder urothelium. Toxicol Appl Pharmacol 2007; 223(3): 246-56.
[http://dx.doi.org/10.1016/j.taap.2007.06.015] [PMID: 17663016]
[89]
La Maestra S, Micale RT, De Flora S, et al. DNA damage in exfoliated cells and histopathological alterations in the urinary tract of mice exposed to cigarette smoke and treated with chemopreventive agents. Carcinogenesis 2013; 34(1): 183-9.
[http://dx.doi.org/10.1093/carcin/bgs314] [PMID: 23042096]
[90]
Dormandy JA, Charbonnel B, Eckland DJ, et al. PROactive Investigators. Secondary prevention of macrovascular events in patients withtype 2 diabetes in the PROactive Study (PROspective pioglitAzoneClinical Trial in macroVascular Events): A randomised controlled trial. Lancet 2005; 366(9493): 1279-89.
[http://dx.doi.org/10.1016/S0140-6736(05)67528-9] [PMID: 16214598]
[91]
Ryder REJ. Pioglitazone: an agent which reduces stroke, myocardial infarction and death and is also a key component of the modern paradigm for the optimum management of type 2 diabetes. Br J Diabetes Vasc Dis 2011; 11(3): 113-20.
[http://dx.doi.org/10.1177/1474651411412658]
[92]
Wilcox R, Bousser MG, Betteridge DJ, et al. PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: Results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007; 38(3): 865-73.
[http://dx.doi.org/10.1161/01.STR.0000257974.06317.49] [PMID: 17290029]
[93]
Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM. PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: Results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007; 49(17): 1772-80.
[http://dx.doi.org/10.1016/j.jacc.2006.12.048] [PMID: 17466227]
[94]
Dormandy JA, Betteridge DJ, Schernthaner G, Pirags V, Norgren L. PROactive investigators. Impact of peripheral arterial disease in patients with diabetes-results from PROactive (PROactive 11). Atherosclerosis 2009; 202(1): 272-81.
[http://dx.doi.org/10.1016/j.atherosclerosis.2008.03.002] [PMID: 18538774]
[95]
Faillie JL, Petit P, Montastruc JL, Hillaire-Buys D. Scientific evidence and controversies about pioglitazone and bladder cancer: Which lessons can be drawn? Drug Saf 2013; 36(9): 693-707.
[http://dx.doi.org/10.1007/s40264-013-0086-y] [PMID: 23868339]
[96]
Hillaire-Buys D, Faillie JL, Montastruc JL. Pioglitazone and bladder cancer. Lancet 2011; 378(9802): 1543-4.
[http://dx.doi.org/10.1016/S0140-6736(11)61662-0] [PMID: 22035550]
[97]
Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR. PROactive investigators. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: An overview of data from PROactive. Drug Saf 2009; 32(3): 187-202.
[http://dx.doi.org/10.2165/00002018-200932030-00002] [PMID: 19338377]
[98]
Ryder RE. Neither evidence from the PROactive study nor the KPNC supports pioglitazone as a tumour promoter. Diabet Med 2015; 32(4): 438-9.
[http://dx.doi.org/10.1111/dme.12703] [PMID: 25773281]
[99]
Ryder RE. Pioglitazone: Reports of its death are greatly exaggerated - it is alive and ready to resume saving lives. Diabet Med 2015; 32(4): e9-e15.
[http://dx.doi.org/10.1111/dme.12736] [PMID: 25773282]
[100]
Erdmann E, Song E, Spanheimer R, van Troostenburg de Bruyn AR, Perez A. Observational follow-up of the PROactive study: A 6-year update. Diabetes Obes Metab 2014; 16(1): 63-74.
[http://dx.doi.org/10.1111/dom.12180] [PMID: 23859428]
[101]
Erdmann E, Harding S, Lam H, Perez A. Ten-year observational follow-up of PROactive: A randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes. Diabetes Obes Metab 2016; 18(3): 266-73.
[http://dx.doi.org/10.1111/dom.12608] [PMID: 26592506]
[102]
Gale EA. Pioglitazone: Are rumours of its death exaggerated? Diabet Med 2015; 32(4): 431-7.
[http://dx.doi.org/10.1111/dme.12708] [PMID: 25773280]
[103]
Kernan WN, Viscoli CM, Furie KL, et al. IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 2016; 374(14): 1321-31.
[http://dx.doi.org/10.1056/NEJMoa1506930] [PMID: 26886418]
[104]
Spence JD, Viscoli CM, Inzucchi SE, et al. IRIS Investigators. Pioglitazone therapy in patients with stroke and prediabetes: A post hoc analysis of the IRIS randomized clinical trial. JAMA Neurol 2019; 76(5): 526-35.
[http://dx.doi.org/10.1001/jamaneurol.2019.0079] [PMID: 30734043]
[105]
Vaccaro O, Masulli M, Nicolucci A, et al. Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group; Italian Diabetes Society. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): A randomised, multicentre trial. Lancet Diabetes Endocrinol 2017; 5(11): 887-97.
[http://dx.doi.org/10.1016/S2213-8587(17)30317-0] [PMID: 28917544]
[106]
Yoshii H, Onuma T, Yamazaki T, et al. PROFIT-J Study group. Effects of pioglitazone on macrovascular events in patients with type 2 diabetes mellitus at high risk of stroke: The PROFIT-J study. J Atheroscler Thromb 2014; 21(6): 563-73.
[http://dx.doi.org/10.5551/jat.21626] [PMID: 24477028]
[107]
Tanaka R, Yamashiro K, Okuma Y, et al. Effects of pioglitazone for secondary stroke prevention in patients with impaired glucose tolerance and newly diagnosed diabetes: The J-SPIRIT study. J Atheroscler Thromb 2015; 22(12): 1305-16.
[http://dx.doi.org/10.5551/jat.30007] [PMID: 26269002]
[108]
DeFronzo RA, Tripathy D, Schwenke DC, et al. ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011; 364(12): 1104-15.
[http://dx.doi.org/10.1056/NEJMoa1010949] [PMID: 21428766]
[109]
Saremi A, Schwenke DC, Buchanan TA, et al. Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2013; 33(2): 393-9.
[http://dx.doi.org/10.1161/ATVBAHA.112.300346] [PMID: 23175674]
[110]
Kaku K, Daida H, Kashiwagi A, et al. Long-term effects of pioglitazone in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity. Curr Med Res Opin 2009; 25(12): 2925-32.
[http://dx.doi.org/10.1185/03007990903328124] [PMID: 19835463]
[111]
Liao HW, Saver JL, Wu YL, Chen TH, Lee M, Ovbiagele B. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: A systematic review and meta-analysis. BMJ Open 2017; 7(1): e013927.
[http://dx.doi.org/10.1136/bmjopen-2016-013927] [PMID: 28057658]
[112]
Sinha B, Ghosal S. Assessing the need for pioglitazone in the treatment of patients with type 2 diabetes: A meta-analysis of its risks and benefits from prospective trials. Sci Rep 2020; 10(1): 15781.
[http://dx.doi.org/10.1038/s41598-020-72967-8] [PMID: 32978507]
[113]
Alam F, Islam MA, Mohamed M, et al. Efficacy and safety of pioglitazone monotherapy in type 2 diabetes mellitus: A systematic review and meta-analysis of randomised controlled trials. Sci Rep 2019; 9(1): 5389.
[http://dx.doi.org/10.1038/s41598-019-41854-2] [PMID: 30926892]
[114]
Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: Interim report of a longitudinal cohort study. Diabetes Care 2011; 34(4): 916-22.
[http://dx.doi.org/10.2337/dc10-1068] [PMID: 21447663]
[115]
Friedman G, Habel L, Boles M, Mcfarland B. Kaiser Permanente Medical Care Program: Division of Research, Northern California, and Center for Health Research, Northwest Division Pharmacoepidemiology. 3rd ed. West Sussex, U.K.: John Wiley & Sons 2000; pp. 263-83.
[http://dx.doi.org/10.1002/0470842555.ch16]
[116]
Ferrara A, Lewis JD, Quesenberry CP Jr, et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care 2011; 34(4): 923-9.
[http://dx.doi.org/10.2337/dc10-1067] [PMID: 21447664]
[117]
Yang X, Chan JC. Comment: Analyses using time-dependent pioglitazone usage in Cox models may lead to wrong conclusions about its association with cancer. Diabetes Care 2011; 34(8): e136.
[http://dx.doi.org/10.2337/dc11-0627] [PMID: 21788639]
[118]
FDA. Drug Safety Communication: Ongoing Safety Review of Actos (pioglitazone) and Potential Increased Risk of Bladder Cancer After Two Years Exposure. Available from: http://www.fda.gov/Drugs/ (Accessed April 29, 2015)
[119]
European Medicines Agency. European Medicines Agency recommends new contra-indications and warnings for pioglitazone to reduce small increased risk of bladder cancer. 2011. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/07/news_detail_001311.jsp&mid=WC0b01ac058004d5cl (Accessed on 12 October, 2013).
[120]
Lewis JD, Habel L, Quesenberry C, et al. Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: Potential for unmeasured confounding in studies of pioglitazone and bladder cancer. Pharmacoepidemiol Drug Saf 2014; 23(6): 636-45.
[http://dx.doi.org/10.1002/pds.3619] [PMID: 24764283]
[121]
Dolin P. Pioglitazone, bladder cancer, and detection bias. J Diabetes 2014; 6(2): 193-4.
[http://dx.doi.org/10.1111/1753-0407.12087] [PMID: 24004505]
[122]
Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: A population-based cohort study. Diabetologia 2012; 55(7): 1953-62.
[http://dx.doi.org/10.1007/s00125-012-2538-9] [PMID: 22460763]
[123]
French medicines agency (AFSSAPS) (2011) Use of medications containing pioglitazone (Actos®, Competact®) Suspended. 2011. Available from: www.afssaps.fr/content/download/34175/447382/version/1/file/Press-release-Suspension-Pioglitazone.pdf (Accessed 12 August, 2011).
[124]
Sadikot SM, Ghosal S. India suspends pioglitazone: Is it justified? Diabetes Metab Syndr 2014; 8(1): 53-6.
[http://dx.doi.org/10.1016/j.dsx.2013.10.020] [PMID: 24661760]
[125]
Singh AK. Polemics of pioglitazone: An appraisal in 2015. Expert Rev Endocrinol Metab 2015; 10(4): 447-58.
[http://dx.doi.org/10.1586/17446651.2015.1054809] [PMID: 30293494]
[126]
Perez AT. Pioglitazone and risk of bladder cancer: Clarification of the design of the French study. Diabetologia 2013; 56(1): 227.
[http://dx.doi.org/10.1007/s00125-012-2767-y] [PMID: 23135221]
[127]
Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 2011; 34(6): 1369-71.
[http://dx.doi.org/10.2337/dc10-2412] [PMID: 21515844]
[128]
Azoulay L, Yin H, Filion KB, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: Nested case-control study. BMJ 2012; 344: e3645.
[http://dx.doi.org/10.1136/bmj.e3645] [PMID: 22653981]
[129]
Wei L, MacDonald TM, Mackenzie IS. Pioglitazone and bladder cancer: A propensity score matched cohort study. Br J Clin Pharmacol 2013; 75(1): 254-9.
[http://dx.doi.org/10.1111/j.1365-2125.2012.04325.x] [PMID: 22574756]
[130]
Mamtani R, Haynes K, Bilker WB, et al. Association between longer therapy with thiazolidinediones and risk of bladder cancer: A cohort study. J Natl Cancer Inst 2012; 104(18): 1411-21.
[http://dx.doi.org/10.1093/jnci/djs328] [PMID: 22878886]
[131]
Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: A meta-analysis. Diabetologia 2006; 49(12): 2819-23.
[http://dx.doi.org/10.1007/s00125-006-0468-0] [PMID: 17021919]
[132]
MacKenzie T, Zens MS, Ferrara A, Schned A, Karagas MR. Diabetes and risk of bladder cancer: Evidence from a case-control study in New England. Cancer 2011; 117(7): 1552-6.
[http://dx.doi.org/10.1002/cncr.25641] [PMID: 21425156]
[133]
Tseng CH. Pioglitazone and bladder cancer: A population-based study of Taiwanese. Diabetes Care 2012; 35(2): 278-80.
[http://dx.doi.org/10.2337/dc11-1449] [PMID: 22210574]
[134]
Tseng CH. Diabetes and risk of bladder cancer: A study using the National Health Insurance database in Taiwan. Diabetologia 2011; 54(8): 2009-15.
[http://dx.doi.org/10.1007/s00125-011-2171-z] [PMID: 21544514]
[135]
Kuo HW, Tiao MM, Ho SC, Yang CY. Pioglitazone use and the risk of bladder cancer. Kaohsiung J Med Sci 2014; 30(2): 94-7.
[http://dx.doi.org/10.1016/j.kjms.2013.09.011] [PMID: 24444539]
[136]
Lee MY, Hsiao PJ, Yang YH, Lin KD, Shin SJ. The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: Bladder cancer and chronic kidney disease. PLoS One 2014; 9(1): e85479.
[http://dx.doi.org/10.1371/journal.pone.0085479] [PMID: 24427312]
[137]
Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM, Chan KA. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology 2012; 55(5): 1462-72.
[http://dx.doi.org/10.1002/hep.25509] [PMID: 22135104]
[138]
Tseng CH. Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: A population-based cohort study using the National Health Insurance in Taiwan. BMC Cancer 2013; 13: 7.
[http://dx.doi.org/10.1186/1471-2407-13-7] [PMID: 23286275]
[139]
Lin HC, Hsu YT, Kachingwe BH, Hsu CY, Uang YS, Wang LH. Dose effect of thiazolidinedione on cancer risk in type 2 diabetes mellitus patients: A six-year population-based cohort study. J Clin Pharm Ther 2014; 39(4): 354-60.
[http://dx.doi.org/10.1111/jcpt.12151] [PMID: 24661226]
[140]
Kao CH, Sun LM, Chen PC, et al. A population-based cohort study in Taiwan-use of insulin sensitizers can decrease cancer risk in diabetic patients? Ann Oncol 2013; 24(2): 523-30.
[http://dx.doi.org/10.1093/annonc/mds472] [PMID: 23110810]
[141]
Hsiao FY, Hsieh PH, Huang WF, Tsai YW, Gau CS. Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: A nested case–control study. Drug Saf 2013; 36(8): 643-9.
[http://dx.doi.org/10.1007/s40264-013-0080-4] [PMID: 23797604]
[142]
Jin SM, Song SO, Jung CH, et al. Risk of bladder cancer among patients with diabetes treated with a 15 mg pioglitazone dose in Korea: A multi-center retrospective cohort study. J Korean Med Sci 2014; 29(2): 238-42.
[http://dx.doi.org/10.3346/jkms.2014.29.2.238] [PMID: 24550651]
[143]
Song SO, Kim KJ, Lee BW, Kang ES, Cha BS, Lee HC. The risk of bladder cancer in Korean diabetic subjects treated with pioglitazone. Diabetes Metab J 2012; 36(5): 371-8.
[http://dx.doi.org/10.4093/dmj.2012.36.5.371] [PMID: 23130322]
[144]
Vallarino C, Perez A, Fusco G, et al. Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights. Clin Drug Investig 2013; 33(9): 621-31.
[http://dx.doi.org/10.1007/s40261-013-0106-9] [PMID: 23881565]
[145]
Oliveria SA, Koro CE, Yood MU, Sowell M. Cancer incidence among patients treated with antidiabetic pharmacotherapy. Diabetes Metab Syndr 2008; 2: 47-57.
[http://dx.doi.org/10.1016/j.dsx.2007.11.002]
[146]
Ramos-Nino ME, MacLean CD, Littenberg B. Association between cancer prevalence and use of thiazolidinediones: Results from the Vermont Diabetes Information System. BMC Med 2007; 5: 17.
[http://dx.doi.org/10.1186/1741-7015-5-17] [PMID: 17584937]
[147]
Sun GE, Wells BJ, Yip K, et al. Gender-specific effects of oral hypoglycaemic agents on cancer risk in type 2 diabetes mellitus. Diabetes Obes Metab 2014; 16(3): 276-83.
[http://dx.doi.org/10.1111/dom.12231] [PMID: 24199848]
[148]
Fujimoto K, Hamamoto Y, Honjo S, et al. Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2013; 99(2): e21-3.
[http://dx.doi.org/10.1016/j.diabres.2012.11.013] [PMID: 23228390]
[149]
Balaji V, Seshiah V, Ashtalakshmi G, Ramanan SG, Janarthinakani M. A retrospective study on finding correlation of pioglitazone and incidences of bladder cancer in the Indian population. Indian J Endocrinol Metab 2014; 18(3): 425-7.
[http://dx.doi.org/10.4103/2230-8210.131223] [PMID: 24944944]
[150]
Riaz A, Khan K, Afreen B, Kazmi I. Bladder cancer in patients with type 2 diabetes treated with pioglitazone, a comparative study. J Ayub Med Coll Abbottabad 2018; 30(3): 356-9.
[PMID: 30465366]
[151]
Lewis JD, Habel LA, Quesenberry CP, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA 2015; 314(3): 265-77.
[http://dx.doi.org/10.1001/jama.2015.7996] [PMID: 26197187]
[152]
Levin D, Bell S, Sund R, et al. Scottish Diabetes Research Network Epidemiology Group. Diabetes and Cancer Research Consortium. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia 2015; 58(3): 493-504.
[http://dx.doi.org/10.1007/s00125-014-3456-9] [PMID: 25481707]
[153]
Colhoun HM, Livingstone SJ, Looker HC, et al. Scottish Diabetes Research Network Epidemiology Group. Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia 2012; 55(11): 2929-37.
[http://dx.doi.org/10.1007/s00125-012-2668-0] [PMID: 22945303]
[154]
Korhonen P, Heintjes EM, Williams R, et al. Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: Retrospective cohort study using datasets from four European countries. BMJ 2016; 354: i3903.
[http://dx.doi.org/10.1136/bmj.i3903] [PMID: 27530399]
[155]
Strongman H, Korhonen P, Williams R, et al. Pioglitazone and risk of mortality in patients with type 2 diabetes: Results from a European multidatabase cohort study. BMJ Open Diabetes Res Care 2017; 5(1): e000364.
[http://dx.doi.org/10.1136/bmjdrc-2016-000364] [PMID: 28761650]
[156]
Strongman H, Christopher S, Majak M, et al. Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: Extended analysis from a European multidatabase cohort study. BMJ Open Diabetes Res Care 2018; 6(1): e000481.
[http://dx.doi.org/10.1136/bmjdrc-2017-000481] [PMID: 29379607]
[157]
Tuccori M, Filion KB, Yin H, Yu OH, Platt RW, Azoulay L. Pioglitazone use and risk of bladder cancer: Population based cohort study. BMJ 2016; 352: i1541.
[http://dx.doi.org/10.1136/bmj.i1541] [PMID: 27029385]
[158]
Han E, Jang SY, Kim G, et al. Rosiglitazone use and the risk of bladder cancer in patients with type 2 diabetes. Medicine (Baltimore) 2016; 95(6): e2786.
[http://dx.doi.org/10.1097/MD.0000000000002786] [PMID: 26871835]
[159]
Mackenzie TA, Zaha R, Smith J, Karagas MR, Morden NE. Diabetes pharmacotherapies and bladder cancer: A medicare epidemiologic study. Diabetes Ther 2016; 7(1): 61-73.
[http://dx.doi.org/10.1007/s13300-016-0152-4] [PMID: 26894755]
[160]
Garry EM, Buse JB, Lund JL, Pate V, Stürmer T. Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes. Diabetes Obes Metab 2018; 20(1): 129-40.
[http://dx.doi.org/10.1111/dom.13049] [PMID: 28661561]
[161]
Garry EM, Buse JB, Gokhale M, et al. Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type-2 diabetes. Diabetes Obes Metab 2019; 21(9): 2096-106.
[http://dx.doi.org/10.1111/dom.13774] [PMID: 31087620]
[162]
Gupta S, Gupta K, Ravi R, et al. Pioglitazone and the risk of bladder cancer: An Indian retrospective cohort study. Indian J Endocrinol Metab 2015; 19(5): 639-43.
[http://dx.doi.org/10.4103/2230-8210.163187] [PMID: 26425474]
[163]
Agrawal P, Jain A, Gautam A, Nigam AK, Pursnani N, Farooqui M. A retrospective study to assess the risk of bladder cancer in type-2 diabetic patients treated with pioglitazone. Perspect Clin Res 2021; 12(1): 9-13.
[http://dx.doi.org/10.4103/picr.PICR_192_18] [PMID: 33816203]
[164]
Shariat SF, Karam JA, Lotan Y, Karakiewizc PI. Critical evaluation of urinary markers for bladder cancer detection and monitoring. Rev Urol 2008; 10(2): 120-35.
[PMID: 18660854]
[165]
Ripamonti E, Azoulay L, Abrahamowicz M, Platt RW, Suissa S. A systematic review of observational studies of the association between pioglitazone use and bladder cancer. Diabet Med 2019; 36(1): 22-35.
[http://dx.doi.org/10.1111/dme.13854] [PMID: 30378165]
[166]
Ray WA. Evaluating medication effects outside of clinical trials: New-user designs. Am J Epidemiol 2003; 158(9): 915-20.
[http://dx.doi.org/10.1093/aje/kwg231] [PMID: 14585769]
[167]
Colmers IN, Bowker SL, Johnson JA. Thiazolidinedione use and cancer incidence in type 2 diabetes: A systematic review and meta-analysis. Diabetes Metab 2012; 38(6): 475-84.
[http://dx.doi.org/10.1016/j.diabet.2012.06.003] [PMID: 23041441]
[168]
Zhu Z, Shen Z, Lu Y, Zhong S, Xu C. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: A meta-analysis. Diabetes Res Clin Pract 2012; 98(1): 159-63.
[http://dx.doi.org/10.1016/j.diabres.2012.05.006] [PMID: 22705039]
[169]
Bosetti C, Rosato V, Buniato D, Zambon A, La Vecchia C, Corrao G. Cancer risk for patients using thiazolidinediones for type 2 diabetes: A meta-analysis. Oncologist 2013; 18(2): 148-56.
[http://dx.doi.org/10.1634/theoncologist.2012-0302] [PMID: 23345544]
[170]
Ferwana M, Firwana B, Hasan R, et al. Pioglitazone and risk of bladder cancer: A meta-analysis of controlled studies. Diabet Med 2013; 30(9): 1026-32.
[http://dx.doi.org/10.1111/dme.12144] [PMID: 23350856]
[171]
He S, Tang YH, Zhao G, Yang X, Wang D, Zhang Y. Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis. Tumour Biol 2014; 35(3): 2095-102.
[http://dx.doi.org/10.1007/s13277-013-1278-x] [PMID: 24092576]
[172]
Turner RM, Kwok CS, Chen-Turner C, Maduakor CA, Singh S, Loke YK. Thiazolidinediones and associated risk of bladder cancer: A systematic review and meta-analysis. Br J Clin Pharmacol 2014; 78(2): 258-73.
[http://dx.doi.org/10.1111/bcp.12306] [PMID: 24325197]
[173]
Monami M, Dicembrini I, Mannucci E. Thiazolidinediones and cancer: Results of a meta-analysis of randomized clinical trials. Acta Diabetol 2014; 51(1): 91-101.
[http://dx.doi.org/10.1007/s00592-013-0504-8] [PMID: 23851465]
[174]
Qu H, Zheng Y, Wang Y, et al. Global and regional effects of bladder cancer risk associated with pioglitazone therapy in patients with diabetes. Sci Rep 2017; 7(1): 15804.
[http://dx.doi.org/10.1038/s41598-017-16074-1] [PMID: 29150684]
[175]
Filipova E, Uzunova K, Kalinov K, Vekov T. Pioglitazone and the risk of bladder cancer: A meta-analysis. Diabetes Ther 2017; 8(4): 705-26.
[http://dx.doi.org/10.1007/s13300-017-0273-4] [PMID: 28623552]
[176]
Li Z, Sun M, Wang F, Shi J, Wang K. Association between pioglitazone use and the risk of bladder cancer among subjects with diabetes mellitus: A dose-response meta-analysis. Int J Clin Pharmacol Ther 2017; 55(3): 210-9.
[http://dx.doi.org/10.5414/CP202670] [PMID: 28025963]
[177]
Yan H, Xie H, Ying Y, et al. Pioglitazone use in patients with diabetes and risk of bladder cancer: a systematic review and meta-analysis. Cancer Manag Res 2018; 10: 1627-38.
[http://dx.doi.org/10.2147/CMAR.S164840] [PMID: 29970962]
[178]
Tang H, Shi W, Fu S, et al. Pioglitazone and bladder cancer risk: A systematic review and meta-analysis. Cancer Med 2018; 7(4): 1070-80.
[http://dx.doi.org/10.1002/cam4.1354] [PMID: 29476615]
[179]
Adil M, Khan RA, Ghosh P, Venkata SK, Kandhare AD, Sharma M. Pioglitazone and risk of bladder cancer in type 2 diabetes mellitus patients: A systematic review and meta-analysis of observational studies using real-world data. Clin Epidemiol Glob Health 2018; 6: 61-8.
[http://dx.doi.org/10.1016/j.cegh.2017.08.002]
[180]
Mehtälä J, Khanfir H, Bennett D, Ye Y, Korhonen P, Hoti F. Pioglitazone use and risk of bladder cancer: a systematic literature review and meta-analysis of observational studies. Diabetol Int 2018; 10(1): 24-36.
[http://dx.doi.org/10.1007/s13340-018-0360-4] [PMID: 30800561]
[181]
Davidson MB, Pan D. An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug’s effect on cardiovascular disease and non-alcoholic steatohepatitis. Diabetes Res Clin Pract 2018; 135: 102-10.
[http://dx.doi.org/10.1016/j.diabres.2017.11.002] [PMID: 29146119]
[182]
Rothman KJ. Induction and latent periods. Am J Epidemiol 1981; 114(2): 253-9.
[http://dx.doi.org/10.1093/oxfordjournals.aje.a113189] [PMID: 7304560]
[183]
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[184]
Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA 2011; 306(7): 737-45.
[http://dx.doi.org/10.1001/jama.2011.1142] [PMID: 21846855]
[185]
Chen HI, Liou SH, Loh CH, Uang SN, Yu YC, Shih TS. Bladder cancer screening and monitoring of 4,4'-methylenebis(2-chloroaniline) exposure among workers in Taiwan. Urology 2005; 66(2): 305-10.
[http://dx.doi.org/10.1016/j.urology.2005.02.031] [PMID: 16098360]
[186]
Zhu Z, Wang X, Shen Z, Lu Y, Zhong S, Xu C. Risk of bladder cancer in patients with diabetes mellitus: An updated meta-analysis of 36 observational studies. BMC Cancer 2013; 13: 310.
[http://dx.doi.org/10.1186/1471-2407-13-310] [PMID: 23803148]
[187]
Montella M, Di Maso M, Crispo A, et al. Metabolic syndrome and the risk of urothelial carcinoma of the bladder: A case-control study. BMC Cancer 2015; 15: 720.
[http://dx.doi.org/10.1186/s12885-015-1769-9] [PMID: 26475132]
[188]
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38(1): 140-9.
[http://dx.doi.org/10.2337/dc14-2441] [PMID: 25538310]
[189]
American Diabetes Association. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2021. Diabetes Care 2021; 44(Suppl. 1): S111-24.
[http://dx.doi.org/10.2337/dc21-S009] [PMID: 33298420]
[190]
Aschenbrenner DS. Updated review confirms potential risk of bladder cancer with pioglitazone. Am J Nurs 2017; 117(4): 25.
[http://dx.doi.org/10.1097/01.NAJ.0000515230.35655.54] [PMID: 28333739]
[191]
Glover R. Review: The presumption of innocence: Evidential and human rights perspectives. IJE & P 2011; 15(1): 89-92.
[http://dx.doi.org/10.1350/ijep.2011.15.1.371]
[192]
Smith CM. Origin and uses of primum non nocere-above all, do no harm! J Clin Pharmacol 2005; 45(4): 371-7.
[http://dx.doi.org/10.1177/0091270004273680] [PMID: 15778417]
[193]
Ernst E. Medicines guilty until proven innocent. Pharm J 2005; 274(7352): 679.
[194]
Lee M, Saver JL, Liao HW, Lin CH, Ovbiagele B. Pioglitazone for secondary stroke prevention: A systematic review and meta-analysis. Stroke 2017; 48(2): 388-93.
[http://dx.doi.org/10.1161/STROKEAHA.116.013977] [PMID: 27999139]
[195]
Satirapoj B, Watanakijthavonkul K, Supasyndh O. Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial. PLoS One 2018; 13(10): e0206722.
[http://dx.doi.org/10.1371/journal.pone.0206722] [PMID: 30379936]
[196]
Yanai H, Adachi H. The low-dose (7.5 mg/day) pioglitazone therapy. J Clin Med Res 2017; 9(10): 821-5.
[http://dx.doi.org/10.14740/jocmr3144w] [PMID: 28912917]
[197]
Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41(12): 2669-701.
[http://dx.doi.org/10.2337/dci18-0033] [PMID: 30291106]
[198]
Ryder REJ, DeFronzo RA. Diabetes medications with cardiovascular protection in the wake of EMPA-REG outcome: The optimal combination may be metformin, pioglitazone and empagliflozin. Br J Diabetes Vasc Dis 2015; 15: 151-4.
[http://dx.doi.org/10.15277/bjdvd.2015.045]
[199]
DeFronzo RA, Chilton R, Norton L, Clarke G, Ryder RE, Abdul-Ghani M. Revitalization of pioglitazone: The optimal agent to be combined with an SGLT2 inhibitor. Diabetes Obes Metab 2016; 18(5): 454-62.
[http://dx.doi.org/10.1111/dom.12652] [PMID: 26919068]
[200]
Papaetis GS. Empagliflozin therapy and insulin resistance-associated disorders: Effects and promises beyond a diabetic state. Arch Med Sci Atheroscler Dis 2021; 6: e57-78.
[http://dx.doi.org/10.5114/amsad.2021.105314] [PMID: 34027215]
[201]
Abdul-Ghani M, DeFronzo RA, Del Prato S, Chilton R, Singh R, Ryder REJ. Cardiovascular disease and type 2 diabetes: Has the dawn of a new era arrived? Diabetes Care 2017; 40(7): 813-20.
[http://dx.doi.org/10.2337/dc16-2736] [PMID: 28637886]
[202]
Suissa S, Azoulay L. Metformin and the risk of cancer: Time-related biases in observational studies. Diabetes Care 2012; 35(12): 2665-73.
[http://dx.doi.org/10.2337/dc12-0788] [PMID: 23173135]
[203]
Bykov K, He M, Franklin JM, Garry EM, Seeger JD, Patorno E. Glucose-lowering medications and the risk of cancer: A methodological review of studies based on real-world data. Diabetes Obes Metab 2019; 21(9): 2029-38.
[http://dx.doi.org/10.1111/dom.13766] [PMID: 31062453]
[204]
Ripamonti E, Azoulay L, Abrahamowicz M, Platt RW, Suissa S. Pioglitazone and bladder cancer: Improving research methods. Diabet Med 2020; 37(5): 898-9.
[http://dx.doi.org/10.1111/dme.14248] [PMID: 31995846]
[205]
Franklin JM, Eddings W, Austin PC, Stuart EA, Schneeweiss S. Comparing the performance of propensity score methods in healthcare database studies with rare outcomes. Stat Med 2017; 36(12): 1946-63.
[PMID: 28208229]
[206]
Patorno E, Gopalakrishnan C, Franklin JM, et al. Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records. Diabetes Obes Metab 2018; 20(4): 974-84.
[http://dx.doi.org/10.1111/dom.13184] [PMID: 29206336]
[207]
Walker JJ, Johnson JA, Wild SH. Diabetes treatments and cancer risk: The importance of considering aspects of drug exposure. Lancet Diabetes Endocrinol 2013; 1(2): 132-9.
[http://dx.doi.org/10.1016/S2213-8587(13)70028-7] [PMID: 24622319]

Rights & Permissions Print Cite
Article Metrics
29
1
© 2024 Bentham Science Publishers | Privacy Policy